These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 28782830

  • 1. Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease.
    Hsu YT, Chang YG, Chang CP, Siew JJ, Chen HM, Tsai CH, Chern Y.
    Mov Disord; 2017 Nov; 32(11):1600-1609. PubMed ID: 28782830
    [Abstract] [Full Text] [Related]

  • 2. Enhanced Na+ -K+ -2Cl- cotransporter 1 underlies motor dysfunction in huntington's disease.
    Hsu YT, Chang YG, Liu YC, Wang KY, Chen HM, Lee DJ, Yang SS, Tsai CH, Lien CC, Chern Y.
    Mov Disord; 2019 Jun; 34(6):845-857. PubMed ID: 30840784
    [Abstract] [Full Text] [Related]

  • 3. Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3.
    Wójtowicz AM, Dvorzhak A, Semtner M, Grantyn R.
    Front Neural Circuits; 2013 Jun; 7():188. PubMed ID: 24324407
    [Abstract] [Full Text] [Related]

  • 4. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A, Martire A, Pepponi R, Varani K, Vincenzi F, Ferraro L, Beggiato S, Tebano MT, Popoli P.
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [Abstract] [Full Text] [Related]

  • 5. Enhanced behavioral sensitivity to the competitive GABA agonist, gaboxadol, in transgenic mice over-expressing hippocampal extrasynaptic alpha6beta GABA(A) receptors.
    Saarelainen KS, Ranna M, Rabe H, Sinkkonen ST, Möykkynen T, Uusi-Oukari M, Linden AM, Lüddens H, Korpi ER.
    J Neurochem; 2008 Apr; 105(2):338-50. PubMed ID: 18021290
    [Abstract] [Full Text] [Related]

  • 6. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
    Kreilaus F, Spiro AS, Hannan AJ, Garner B, Jenner AM.
    J Huntingtons Dis; 2015 Apr; 4(4):305-18. PubMed ID: 26639223
    [Abstract] [Full Text] [Related]

  • 7. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M.
    Neuroscience; 2009 Sep 29; 163(1):456-65. PubMed ID: 19524019
    [Abstract] [Full Text] [Related]

  • 8. Enhanced striatopallidal gamma-aminobutyric acid (GABA)A receptor transmission in mouse models of huntington's disease.
    Perez-Rosello T, Gelman S, Tombaugh G, Cachope R, Beaumont V, Surmeier DJ.
    Mov Disord; 2019 May 29; 34(5):684-696. PubMed ID: 30726572
    [Abstract] [Full Text] [Related]

  • 9. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.
    Denovan-Wright EM, Robertson HA.
    Neuroscience; 2000 May 29; 98(4):705-13. PubMed ID: 10891614
    [Abstract] [Full Text] [Related]

  • 10. Comparing the discriminative stimulus effects of modulators of GABAA receptors containing α4-δ subunits with those of gaboxadol in rats.
    Zanettini C, Pressly JD, Ibarra MH, Smith KR, Gerak LR.
    Psychopharmacology (Berl); 2016 May 29; 233(10):2005-13. PubMed ID: 26900079
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Regional and subcellular distribution of GABAC ρ3 receptor in brain of R6/2 mouse model of Huntington's disease.
    Kumar U, Heer M, Somvanshi RK.
    Neurosci Lett; 2017 Feb 15; 640():81-87. PubMed ID: 28104430
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
    Kedaigle AJ, Reidling JC, Lim RG, Adam M, Wu J, Wassie B, Stocksdale JT, Casale MS, Fraenkel E, Thompson LM.
    Hum Mol Genet; 2020 Jan 15; 29(2):202-215. PubMed ID: 31696228
    [Abstract] [Full Text] [Related]

  • 17. delta-Subunit containing GABAA receptor knockout mice are less sensitive to the actions of 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridin-3-ol.
    Boehm SL, Homanics GE, Blednov YA, Harris RA.
    Eur J Pharmacol; 2006 Jul 17; 541(3):158-62. PubMed ID: 16777089
    [Abstract] [Full Text] [Related]

  • 18. Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence.
    Liang J, Cagetti E, Olsen RW, Spigelman I.
    J Pharmacol Exp Ther; 2004 Sep 17; 310(3):1234-45. PubMed ID: 15126642
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Deletion of the alpha1 or beta2 subunit of GABAA receptors reduces actions of alcohol and other drugs.
    Blednov YA, Jung S, Alva H, Wallace D, Rosahl T, Whiting PJ, Harris RA.
    J Pharmacol Exp Ther; 2003 Jan 17; 304(1):30-6. PubMed ID: 12490572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.